参麦注射液对肝癌射频消融术后复发转移的影响

Shenmai Injection Has Effect on Recurrence and Metastasis of Liver Cancer After Radiofrequency Ablation

目的:观察参麦注射液对肝癌射频消融术后复发转移的影响。方法:将原发性肝癌患者150例随机分为观察组和对照组各75例,对照组患者给予射频消融治疗,观察组在对照组的基础上联合参麦注射液治静脉滴注治疗;治疗1月后观测2组治疗前后血清甲胎蛋白(AFP)、血管内皮细胞生长因子(VEGF)、总胆红素(TB)、丙氨酸转氨酶(ALT)水平变化,1年内统计2组存活及转移复发情况。结果:治疗后,2组患者VEGF、AFP水平均较治疗前下降(P <0.05);且治疗组上述指标下降较对照组更显著(P <0.05)。治疗后,2组患者TB、ALT水平均较治疗前升高(P <0.05);但2组间TB、ALT水平比较,差异无统计学意义(P> 0.05)。1年存活率、复发转移率观察组分别为90.67%、16.00%,对照组分别为66.67%、41.33%,2组比较,差异均有统计学意义(P <0.05)。结论:参麦注射液可抑制肝癌射频消融术后VEGF、AFP水平,提高患者存活率,降低转移复发率。

Objective： To observe the effect of Shenmai injection on the recurrence and metastasis of patients with liver cancer after radiofrequency ablation. Methods： Divided 150 cases of patients with primary liver cancer into two groups randomly, 75 cases in each group. The control group received radiofrequency ablation for treatment, while the observation group additionally received intravenous drip of Shenmai injection based on the treatment of the control group. After one month of treatment, observed changes in levels of serum alpha-fetoprotein （AFP）, vascular endothelial growth factor （VEGF）, total bilirubin （TB） and alanine aminotransferase （ALT） levels before and after treatment. After treatment, observed levels of Alpha-fetoprotein （AFP） in serum, vascular endothelial growth factor （VEGF）, total bilirubin（TB） and alanine aminotransferase （ALT） before and after treatment. Counted the condition of survival, recurrence and metastasis in the two groups in one year. Results： After treatment, levels of the VEGF and AFP in the two groups were decreased when compared with those before treatment （P 〈 0.05）; the above two indexes in the treatment group were decreased more significantly than those in the control group （P 〈 0.05）. After treatment, levels of the TB and ALT in the two groups were increased when compared with those before treatment （P 〈 0.05）. No significant difference was found in the comparison of levels of the TB and ALT between the two groups （P 〉 0.05）. The one-year survival rate and the recurrence and metastasis rate were 90.67% and 16.00% in the observation group, and 66.67% and 41.33% in the control group, respectively, differences being significant （P 〈 0.05）. Conclusion： Shenmai injection can inhibit levels of VEGF and AFP of patients with liver cancer after radiofrequency ablation, improve the survival rate and reduce the recurrence and metastasis rate.